Clinical Trial Update: Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma [Phase 1]

View source ↗

Summary

Phase 1 study of Nous-PEV for melanoma and non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Nous-PEV

Snippet

Sponsor: Nouscom SRL | Conditions: Melanoma (Skin), Non-Small-Cell Lung Carcinoma | Phase 1 | Status: TERMINATED